Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients

References

• Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010;15:5–13.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–2.
   PubMed Web of Science ®Google Scholar
• Representatives EGB. EASL–EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908–43.
   PubMed Web of Science ®Google Scholar
• Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012;55:483–90.
   PubMed Web of Science ®Google Scholar
• Singal A, Volk M, Waljee A, Salgia R, Higgins P, Rogers M, et al. Meta‐analysis: surveillance with ultrasound for early‐stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37–47.
   PubMed Web of Science ®Google Scholar
• Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993;328:1802–6.
   PubMed Web of Science ®Google Scholar
• Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T. A clinical study of lectin‐reactive alpha‐fetoprotein as an early indicator of hepatocellular carcinoma in the follow‐up of cirrhotic patients. Hepatology 2005;22:802–7.
   Google Scholar
• Yamashita F, Tanaka M, Satomura S, Tanikawa K. Monitoring of lectinreactive alpha-fetoproteins in patients with hepatocellular carcinoma treated using transcatheter arterial embolization. Eur J Gastroenterol Hepatol 1995;7:627–33.
   PubMed Web of Science ®Google Scholar
• Yamashita F, Tanaka M, Satomura S, Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996;111:996.
   PubMed Web of Science ®Google Scholar
• Kumada T, Nakano S, Takeda I, Kiriyama S, Sone Y, Hayashi K, et al. Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol 1999;30:125.
   PubMed Web of Science ®Google Scholar
• Kusaba T. Relationship between Lens culinaris agglutinin reactive alpha-fetoprotein and biological features of hepatocellular carcinoma. Kurume Med J 1998;45:113–20.
   PubMedGoogle Scholar
• Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, Satomura M, et al. Automated immunoassay system for AFP–L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Analyt Biochem 2009;388:306–11.
   PubMed Web of Science ®Google Scholar
• Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Kanke F, et al. Clinical utility of highly sensitive Lens culinaris agglutinin‐reactive alpha‐fetoprotein in hepatocellular carcinoma patients with alpha‐fetoprotein < 20 ng/mL. Cancer Sci 2011;102:1025–31.
   PubMed Web of Science ®Google Scholar
• Durazo FA, Blatt LM, Corey WG, Lin J-H, Han S, Saab S, et al. Des-γ-carboxyprothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2008;23:1541–8.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. α-fetoprotein, des-γ carboxyprothrombin, and lectin-bound α-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110–18.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis2010;30:61–74.
   PubMed Web of Science ®Google Scholar
• Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54:411–18.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006;101:2038–43.
   PubMed Web of Science ®Google Scholar
• Hu B, Tian X, Sun J, Meng X. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci 2013;14:23559–80.
   PubMed Web of Science ®Google Scholar
• Oda K, Ido A, Tamai T, Matsushita M, Kumagai K, Mawatari S-i, et al. Highly sensitive lens culinaris agglutinin-reactive α-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease. Oncol Rep 2011;26:1227.
   PubMed Web of Science ®Google Scholar
• Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, et al. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol 2014;49:555–63.
   PubMed Web of Science ®Google Scholar
• Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 2007;3:79–87.
   PubMedGoogle Scholar
• Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomark Prev 2014;23:144–53.
   PubMed Web of Science ®Google Scholar
• Yuen M-F, Lai C-L. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005;19:91–9.
   PubMed Web of Science ®Google Scholar
• Kim DY, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, et al. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 2007;72:52–7.
   PubMed Web of Science ®Google Scholar
• Kim D, Han K. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2–14.
   PubMed Web of Science ®Google Scholar
• Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of Lens culinaris agglutinin-reactive α-fetoprotein and des-γ-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 2007;52:776–82.
   PubMed Web of Science ®Google Scholar
• Taketa K, Endo Y, Sekiya C, Tanikawa K, Koji T, Taga H, et al. A collaborative study for the evaluation of lectin-reactive α-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993;53:5419–23.
   PubMed Web of Science ®Google Scholar
• Taketa K. α‐Fetoprotein: reevaluation in hepatology. Hepatology 1990;12:1420–32.
   PubMed Web of Science ®Google Scholar
• Morimoto M, Numata K, Nozaki A, Kondo M, Moriya S, Taguri M, et al. Novel Lens culinaris agglutinin-reactive fraction of α-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low α-fetoprotein concentrations. Int J Clin Oncol 2012;17:373–9.
   PubMed Web of Science ®Google Scholar
• Oka H, Saito A, Ito K, Kumada T, Satomura S, Kasugai H, et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin‐reactive α‐fetoprotein1. J Gastroenterol Hepatol 2001;16:1378–83.
   PubMed Web of Science ®Google Scholar